Novobismol, 120 mg 56 pcs.

Novobismol is an anti-ulcer agent with bactericidal activity against Helicobacter pylori.

It also has anti-inflammatory and astringent action.

In the acidic environment of the stomach it forms insoluble bismuth oxychloride and citrate and also forms chelated compounds with protein substrate in the form of a protective film on the surface of ulcers and erosions.

With increased synthesis of prostaglandin E, mucus formation and hydrocarbonate secretion, it stimulates the activity of cytoprotective mechanisms and increases resistance of gastrointestinal mucosa to pepsin, hydrochloric (hydrochloric) acid, enzymes and bile salts.

Leads to the accumulation of epidermal growth factor in the defect area.

Reduces the activity of pepsin and pepsinogen.

Indications

Peptic ulcer of the stomach and duodenum in the acute phase (including those associated with Helicobacter pylori);

chronic gastritis and gastroduodenitis in the acute phase (including those associated with Helicobacter pylori);

irritable bowel syndrome, which occurs predominantly with symptoms of diarrhea;

functional dyspepsia not associated with organic gastrointestinal diseases.

Pharmacological effect

Novobismol is an antiulcer agent with bactericidal activity against Helicobacter pylori.

It also has anti-inflammatory and astringent effects.

In the acidic environment of the stomach, insoluble bismuth oxychloride and citrate are formed, and chelate compounds are formed with the protein substrate in the form of a protective film on the surface of ulcers and erosions.

By increasing the synthesis of prostaglandin E, mucus formation and bicarbonate secretion, it stimulates the activity of cytoprotective mechanisms, increases the resistance of the gastrointestinal mucosa to the effects of pepsin, hydrochloric (hydrochloric) acid, enzymes and bile salts.

Leads to the accumulation of epidermal growth factor in the defect area.

Reduces the activity of pepsin and pepsinogen.

Special instructions

Novobismol should not be used for more than 8 weeks.

During treatment, it is not recommended to exceed the established daily doses for adults and children.

At the end of the course of treatment in recommended doses, the concentration of the active substance in the blood plasma does not exceed 3-58 mcg/l, and intoxication is observed only at concentrations of more than 100 mcg/l.

During use, stool may turn black due to the formation of bismuth sulfide.

Sometimes there is a slight darkening of the tongue.

Active ingredient

Bismuth tripotassium dicitrate

Composition

Active ingredients:

bismuth tripotassium dicitrate 304.6 mg, which corresponds to the content of bismuth oxide 120 mg;

Excipients:

corn starch – 70.6 mg,

povidone K 30 – 17.7 mg,

potassium polyacrylate – 23.6 mg,

macrogol 6000 – 6.0 mg,

magnesium stearate – 2.0 mg

Pregnancy

Contraindicated for use during pregnancy and lactation (breastfeeding).

Contraindications

Severe renal dysfunction, pregnancy, lactation, hypersensitivity to bismuth tripotassium dicitrate.

Side Effects

From the gastrointestinal tract: nausea, vomiting, increased bowel movements, constipation.

Allergic reactions: skin rash, itching.

Other: with long-term use in high doses – encephalopathy associated with the accumulation of bismuth in the central nervous system.

Interaction

If you take other medicines at the same time, as well as food and liquids, in particular antacids, milk, fruits and fruit juices, the effectiveness of bismuth tripotassium dicitrate may change.

Storage conditions

In a dry place, protected from light, at a temperature not exceeding 25 °C

Shelf life

4 years

Manufacturer

Alium JSC, Russia